| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Molecular Oncology, Markers, Clinical Correlates |
1 Clinical Genetics Service, Department of Medicine, 2 Department of Epidemiology and Biostatistics, and 3 Urology Service, Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, New York
ABSTRACT
Purpose: The Breast Cancer Linkage Consortium and other family-based ascertainments have suggested that male carriers of BRCA mutations are at increased risk of prostate cancer. Several series looking at the frequency of BRCA mutations in unselected patients with prostate cancer have not confirmed this finding. To clarify this issue, we conducted a large case-control study.
Experimental Design: Blood specimens from 251 unselected Ashkenazi men with prostate cancer were screened for the presence of one of the three common Ashkenazi founder mutations in BRCA1 and BRCA2. The incidence of founder mutations was compared with the incidence of founder mutations in 1472 male Ashkenazi volunteers without prostate cancer using logistic regression analysis after adjusting for age.
Results: Thirteen (5.2%) cases had a deleterious mutation in BRCA1 or BRCA2 compared with 28 (1.9%) controls. After adjusting for age, the presence of a BRCA1 or BRCA2 mutation was associated with the development of prostate cancer (odds ratio, 3.41; 95% confidence interval, 1.64–7.06; P = 0.001). When results were stratified by gene, BRCA2 mutation carriers demonstrated an increased risk of prostate cancer (odds ratio, 4.78; 95% confidence interval, 1.87–12.25; P = 0.001), whereas the risk in BRCA1 mutation carriers was not significantly increased.
Conclusions: BRCA2 mutations are more likely to be found in unselected individuals with prostate cancer than age-matched controls. These results support the hypothesis that deleterious mutations in BRCA2 are associated with an increased risk of prostate cancer.
This article has been cited by other articles:
|
|
 |
|
  P. SOORIAKUMARAN, P. MACANAS-PIRARD, G. BUCCA, A. HENDERSON, S.E.M. LANGLEY, R.W. LAING, C.P. SMITH, E.E. LAING, and H.M. COLEY A Gene Expression Profiling Approach Assessing Celecoxib in a Randomized Controlled Trial in Prostate Cancer Cancer Genomics Proteomics, March 1, 2009; 6(2): 93 - 99. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Schayek, K. Haugk, S. Sun, L. D. True, S. R. Plymate, and H. Werner Tumor Suppressor BRCA1 Is Expressed in Prostate Cancer and Controls Insulin-like Growth Factor I Receptor (IGF-IR) Gene Transcription in an Androgen Receptor-Dependent Manner Clin. Cancer Res., March 1, 2009; 15(5): 1558 - 1565. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. Agalliu, R. Gern, S. Leanza, and R. D. Burk Associations of High-Grade Prostate Cancer with BRCA1 and BRCA2 Founder Mutations Clin. Cancer Res., February 1, 2009; 15(3): 1112 - 1120. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. A. Ostrander and M. S. Udler The Role of the BRCA2 Gene in Susceptibility to Prostate Cancer Revisited Cancer Epidemiol. Biomarkers Prev., August 1, 2008; 17(8): 1843 - 1848. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Tryggvadottir, L. Vidarsdottir, T. Thorgeirsson, J. G. Jonasson, E. J. Olafsdottir, G. H. Olafsdottir, T. Rafnar, S. Thorlacius, E. Jonsson, J. E. Eyfjord, et al. Prostate Cancer Progression and Survival in BRCA2 Mutation Carriers J Natl Cancer Inst, June 20, 2007; 99(12): 929 - 935. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Harlap, O. Paltiel, Y. Friedlander, R. Calderon-Margalit, L. Deutsch, K. R. Kleinhaus, O. Manor, A. I. Neugut, M. Opler, M. C. Perrin, et al. Prostate Cancer in Fathers With Fewer Male Offspring: the Jerusalem Perinatal Study Cohort J Natl Cancer Inst, January 3, 2007; 99(1): 77 - 81. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. J. Hall and O. I. Olopade Disparities in Genetic Testing: Thinking Outside the BRCA Box J. Clin. Oncol., May 10, 2006; 24(14): 2197 - 2203. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. B. Travis, C. S. Rabkin, L. M. Brown, J. M. Allan, B. P. Alter, C. B. Ambrosone, C. B. Begg, N. Caporaso, S. Chanock, A. DeMichele, et al. Cancer Survivorship--Genetic Susceptibility and Second Primary Cancers: Research Strategies and Recommendations J Natl Cancer Inst, January 4, 2006; 98(1): 15 - 25. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. A. Narod and K. Offit Prevention and Management of Hereditary Breast Cancer J. Clin. Oncol., March 10, 2005; 23(8): 1656 - 1663. [Full Text] [PDF]
|
|
|
|
|
|
J. E. Garber and K. Offit Hereditary Cancer Predisposition Syndromes J. Clin. Oncol., January 10, 2005; 23(2): 276 - 292. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
